Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-608 in Moderate-to-Severe Plaque Psoriasis
NCT05604898Phase 2Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 608 in plaque psoriasis, sponsored by 3S Guojian Pharmaceutical. Status: unknown.
02
Drugs
608
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05604898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604898.